MNOV Stock Summary and Trading Ideas (Medicinova | NASDAQ:MNOV)

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Medicinova trades on the NASDAQ stock market under the symbol MNOV.

As of April 27, 2026, MNOV stock price climbed to $1.39 with 34,293 million shares trading.

MNOV has a beta of 0.38, meaning it tends to be less sensitive to market movements. MNOV has a correlation of 0.01 to the broad based SPY ETF.

MNOV has a market cap of $68.42 million. This is considered a Micro Cap stock.

In the last 3 years, MNOV traded as high as $2.66 and as low as $1.12.

The top ETF exchange traded funds that MNOV belongs to (by Net Assets): VXF, IWC.

MNOV has underperformed the market in the last year with a price return of -9.7% while the SPY ETF gained +32.0%. MNOV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -25.3% and -6.7%, respectively, while the SPY returned +3.9% and +5.1%, respectively.

MNOV support price is $1.33 and resistance is $1.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MNOV shares will trade within this expected range on the day.